About Pediatric Solid Tumors

About Pediatric Solid Tumors

Both preclinical and clinical studies involving pediatric solid and CNS tumors have shown an aberration of mTOR pathway. In addition, these studies have demonstrated that inhibition of the mTOR pathway has significant efficacy impeding growth of these tumors.

A phase 1 study has been initiated with the Children’s Oncology Group in which pediatric patients with recurrent or refractory solid tumors including CNS tumors, are treated with a combination of ABI-009 + temozomide + irinotecan (NCT02975882).

This study includes patients with osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma, gliomas etc.

Pediatric Solid Tumors

March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and other children living with treatment-resistant or intractable epilepsy. For reasons largely unknown, seizures in this subset of children persist long past their discovery in early childhood despite being treated with multiple medications and undergoing surgery to remove the affected parts of their brain. Diagnosed with epilepsy at age 5, life for Dameral has always come with seizures attached. When his seizures returned after a second brain surgery shortly after his 16th birthday, his mom Linley Allen, hoped for a medical breakthrough. “We needed to find something else since another surgery was out of the question,” Allen said. “We had heard about a drug being studied for a more severe seizure condition. I kept holding onto hope that it might be expanded to treat Shanny’s type of seizures because it was all we had at the time.”   See all and the original News article here: New Drug Trial Gives Hope for Treatment-Resistant Epilepsy